{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T23:59:28Z","timestamp":1786751968734,"version":"build-2736575974"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100016807","name":"Natural Science Foundation of Shenyang Municipality","doi-asserted-by":"publisher","award":["23-503-6-12"],"award-info":[{"award-number":["23-503-6-12"]}],"id":[{"id":"10.13039\/100016807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010086","name":"Foundation of Liaoning Province Education Administration","doi-asserted-by":"publisher","award":["LJKFZ20220177"],"award-info":[{"award-number":["LJKFZ20220177"]}],"id":[{"id":"10.13039\/501100010086","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005047","name":"Liaoning Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2022JH2\/101300090"],"award-info":[{"award-number":["2022JH2\/101300090"]}],"id":[{"id":"10.13039\/501100005047","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.leukres.2024.107615","type":"journal-article","created":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T13:10:30Z","timestamp":1730812230000},"page":"107615","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Advances in the treatment of mantle cell lymphoma with BTK inhibitors"],"prefix":"10.1016","volume":"147","author":[{"given":"Jiwei","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimei","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiying","family":"Duo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2024.107615_bib1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11899-021-00605-9","article-title":"High-risk mantle cell lymphoma in the era of novel agents","volume":"16","author":"Nabrinsky","year":"2021","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/j.leukres.2024.107615_bib2","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.hoc.2020.06.012","article-title":"Key Clinical and Translational Research Questions to Address Unmet Needs in Mantle Cell Lymphoma","volume":"34","author":"Rodgers, Jr","year":"2020","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.leukres.2024.107615_bib3","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13045-020-00961-8","article-title":"Advances in the assessment of minimal residual disease in mantle cell lymphoma","volume":"13","author":"Jung","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.leukres.2024.107615_bib4","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/bjh.17419","article-title":"Mantle cell lymphoma - advances in molecular biology, prognostication and treatment approaches","volume":"195","author":"Silkenstedt","year":"2021","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2024.107615_bib5","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.hoc.2020.05.003","article-title":"Cell cycle dysregulation in mantle cell lymphoma: genomics and therapy","volume":"34","author":"Wang","year":"2020","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.leukres.2024.107615_bib6","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.hoc.2020.06.002","article-title":"Watch and wait in mantle cell lymphoma","volume":"34","author":"Lee","year":"2020","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.leukres.2024.107615_bib7","doi-asserted-by":"crossref","DOI":"10.1172\/JCI153283","article-title":"Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma","volume":"132","author":"Yi","year":"2022","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.leukres.2024.107615_bib8","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3324\/haematol.2014.119115","article-title":"N. European Mantle Cell Lymphoma, The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?","volume":"101","author":"Dreyling","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2024.107615_bib9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13045-018-0556-x","article-title":"Current trials for frontline therapy of mantle cell lymphoma","volume":"11","author":"Steiner","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.leukres.2024.107615_bib10","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11523-021-00857-8","article-title":"Bruton tyrosine kinase inhibitors in B-cell malignancies: their use and differential features","volume":"17","author":"Shirley","year":"2022","journal-title":"Target Oncol."},{"key":"10.1016\/j.leukres.2024.107615_bib11","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.beha.2017.10.010","article-title":"Novel therapies for relapsed\/refractory mantle cell lymphoma","volume":"31","author":"Arora","year":"2018","journal-title":"Best. Pr. Res Clin. Haematol."},{"key":"10.1016\/j.leukres.2024.107615_bib12","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/bjh.14870","article-title":"Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies","volume":"179","author":"Rule","year":"2017","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2024.107615_bib13","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41417-018-0022-5","article-title":"Genomic landscape and prognostic analysis of mantle cell lymphoma","volume":"25","author":"Yang","year":"2018","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.leukres.2024.107615_bib14","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"Low grade lymphoma study, n. european mantle cell lymphoma, A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107615_bib15","first-page":"1","article-title":"Multiple gene knockdown strategies for investigating the properties of human leukemia stem cells and exploring new therapies","volume":"171","author":"Wu","year":"2022","journal-title":"Methods Cell Biol."},{"key":"10.1016\/j.leukres.2024.107615_bib16","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1600-065X.2008.00741.x","article-title":"Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain","volume":"228","author":"Mohamed","year":"2009","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.leukres.2024.107615_bib17","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1182\/blood-2006-04-015586","article-title":"Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma","volume":"108","author":"Rudelius","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107615_bib18","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.clml.2013.04.003","article-title":"Clinical efficacy and management of temsirolimus in patients with relapsed or refractory mantle cell lymphoma","volume":"13","author":"Coiffier","year":"2013","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.leukres.2024.107615_bib19","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1158\/2159-8290.CD-14-0098","article-title":"Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma","volume":"4","author":"Chiron","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.leukres.2024.107615_bib20","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/ni0302-221","article-title":"NF-kappaB at the crossroads of life and death","volume":"3","author":"Karin","year":"2002","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.leukres.2024.107615_bib21","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.1182\/blood-2005-10-4042","article-title":"Constitutive NF-kappaB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas","volume":"107","author":"Fu","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107615_bib22","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13045-018-0621-5","article-title":"NF-kappaB signaling and its relevance to the treatment of mantle cell lymphoma","volume":"11","author":"Balaji","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.leukres.2024.107615_bib23","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/path.1768","article-title":"Expression of the NF-kappaB targets BCL2 and BIRC5\/Survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively","volume":"206","author":"Tracey","year":"2005","journal-title":"J. Pathol."},{"key":"10.1016\/j.leukres.2024.107615_bib24","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/nrm2717","article-title":"Proximal events in Wnt signal transduction","volume":"10","author":"Angers","year":"2009","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.leukres.2024.107615_bib25","first-page":"244","article-title":"Biological and clinical significance of GSK-3beta in mantle cell lymphoma--an immunohistochemical study","volume":"3","author":"Chung","year":"2010","journal-title":"Int J. Clin. Exp. Pathol."},{"key":"10.1016\/j.leukres.2024.107615_bib26","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/417299a","article-title":"Hedgehog regulates cell growth and proliferation by inducing Cyclin D and Cyclin E","volume":"417","author":"Duman-Scheel","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2024.107615_bib27","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1158\/1535-7163.MCT-07-2118","article-title":"Targeting of sonic hedgehog-GLI signaling: a potential strategy to improve therapy for mantle cell lymphoma","volume":"7","author":"Hegde","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.leukres.2024.107615_bib28","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.drudis.2013.06.001","article-title":"The background, discovery and clinical development of BCR-ABL inhibitors","volume":"18","author":"Lambert","year":"2013","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.leukres.2024.107615_bib29","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jaci.2013.01.046","article-title":"B-cell biology and development","volume":"131","author":"Pieper","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.leukres.2024.107615_bib30","doi-asserted-by":"crossref","first-page":"329","DOI":"10.4049\/jimmunol.182.1.329","article-title":"Btk regulates B cell receptor-mediated antigen processing and presentation by controlling actin cytoskeleton dynamics in B cells","volume":"182","author":"Sharma","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.leukres.2024.107615_bib31","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.leukres.2013.07.028","article-title":"Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis","volume":"37","author":"Cinar","year":"2013","journal-title":"Leuk. Res"},{"key":"10.1016\/j.leukres.2024.107615_bib32","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1177\/1078155220915956","article-title":"The role of Bruton's tyrosine kinase inhibitors in the management of mantle cell lymphoma","volume":"26","author":"Hanna","year":"2020","journal-title":"J. Oncol. Pharm. Pr."},{"key":"10.1016\/j.leukres.2024.107615_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128549","article-title":"Optimization of a novel piperazinone series as potent selective peripheral covalent BTK inhibitors","volume":"60","author":"Ma","year":"2022","journal-title":"Bioorg. Med Chem. Lett."},{"key":"10.1016\/j.leukres.2024.107615_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.103212","article-title":"Clinical efficacy and safety of first-line treatments in patients with mantle cell lymphoma: a systematic literature review","volume":"158","author":"Monga","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.leukres.2024.107615_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114232","article-title":"Recent development of BTK-based dual inhibitors in the treatment of cancers","volume":"233","author":"Ran","year":"2022","journal-title":"Eur. J. Med Chem."},{"key":"10.1016\/j.leukres.2024.107615_bib36","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1182\/blood-2015-04-639542","article-title":"Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib","volume":"126","author":"Sun","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107615_bib37","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1756-8722-6-59","article-title":"Ibrutinib and novel BTK inhibitors in clinical development","volume":"6","author":"Akinleye","year":"2013","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.leukres.2024.107615_bib38","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.annonc.2021.08.1990","article-title":"Front-line chemo-immunotherapy is not inferior to ibrutinib in CLL","volume":"32","author":"van Gelder","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.leukres.2024.107615_bib39","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2024.107615_bib40","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/bjh.15108","article-title":"Ibrutinib resistance in mantle cell lymphoma: clinical, molecular and treatment aspects","volume":"181","author":"Hershkovitz-Rokah","year":"2018","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2024.107615_bib41","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1182\/blood-2014-08-597914","article-title":"A phase 1\/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed\/refractory non-Hodgkin lymphoma","volume":"125","author":"Maddocks","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107615_bib42","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","article-title":"Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial","volume":"391","author":"Wang","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2024.107615_bib43","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1038\/s41375-019-0575-9","article-title":"Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma","volume":"33","author":"Wang","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2024.107615_bib44","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.leukres.2024.107615_bib45","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1182\/blood.2019003715","article-title":"Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib","volume":"136","author":"Sun","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107615_bib46","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1182\/bloodadvances.2020004074","article-title":"Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma","volume":"5","author":"Tam","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2024.107615_bib47","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/bloodadvances.2021006083","article-title":"Zanubrutinib monotherapy in relapsed\/refractory indolent non-Hodgkin lymphoma","volume":"6","author":"Phillips","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2024.107615_bib48","doi-asserted-by":"crossref","first-page":"7923","DOI":"10.1021\/acs.jmedchem.9b00687","article-title":"Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase","volume":"62","author":"Guo","year":"2019","journal-title":"J. Med Chem."},{"key":"10.1016\/j.leukres.2024.107615_bib49","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood.2021014162","article-title":"Zanubrutinib in relapsed\/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study","volume":"139","author":"Song","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107615_bib50","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1182\/blood-2015-08-664086","article-title":"A phase 1 clinical trial of the selective BTK inhibitor ONO\/GS-4059 in relapsed and refractory mature B-cell malignancies","volume":"127","author":"Walter","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107615_bib51","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1038\/s41375-019-0658-7","article-title":"Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton's tyrosine kinase inhibitor tirabrutinib (GS\/ONO-4059)","volume":"34","author":"Rule","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2024.107615_bib52","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.hoc.2020.06.007","article-title":"Current role and emerging evidence for bruton tyrosine kinase inhibitors in the treatment of mantle cell lymphoma","volume":"34","author":"Bond","year":"2020","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.leukres.2024.107615_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagen.2020.129531","article-title":"Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition","volume":"1864","author":"Liclican","year":"2020","journal-title":"Biochim Biophys. Acta Gen. Subj."},{"key":"10.1016\/j.leukres.2024.107615_bib54","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S0140-6736(21)00235-X","article-title":"Pirtobrutinib shows evidence to inaugurate a third generation of BTK inhibitors","volume":"397","author":"Michot","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2024.107615_bib55","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2024.107615_bib56","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s40744-019-00182-7","article-title":"Spebrutinib (CC-292) Affects markers of B cell activation, chemotaxis, and osteoclasts in patients with rheumatoid arthritis: results from a mechanistic study","volume":"7","author":"Schafer","year":"2020","journal-title":"Rheuma Ther."},{"key":"10.1016\/j.leukres.2024.107615_bib57","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1124\/jpet.113.203489","article-title":"Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans","volume":"346","author":"Evans","year":"2013","journal-title":"J. Pharm. Exp. Ther."},{"key":"10.1016\/j.leukres.2024.107615_bib58","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1038\/leu.2014.69","article-title":"A novel Bruton's tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity","volume":"28","author":"Eda","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2024.107615_bib59","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s40265-021-01482-5","article-title":"Orelabrutinib: first approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.leukres.2024.107615_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101682","article-title":"Evaluation of orelabrutinib monotherapy in patients with relapsed or refractory Waldenstrom's macroglobulinemia in a single-arm, multicenter, open-label, phase 2 study","volume":"52","author":"Cao","year":"2022","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.leukres.2024.107615_bib61","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1021\/acschembio.6b00480","article-title":"Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations","volume":"11","author":"Johnson","year":"2016","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.leukres.2024.107615_bib62","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3324\/haematol.2021.280061","article-title":"Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies","volume":"107","author":"Allan","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2024.107615_bib63","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1182\/blood.2021011516","article-title":"Evaluation of vecabrutinib as a model for noncovalent BTK\/ITK inhibition for treatment of chronic lymphocytic leukemia","volume":"139","author":"Jebaraj","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107615_bib64","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s11899-019-00512-0","article-title":"Targeting BTK in CLL: beyond Ibrutinib","volume":"14","author":"Bond","year":"2019","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/j.leukres.2024.107615_bib65","doi-asserted-by":"crossref","DOI":"10.3390\/jpm11080764","article-title":"Non-covalent BTK inhibitors-the new BTKids on the block for B-Cell malignancies","volume":"11","author":"Lewis","year":"2021","journal-title":"J. Pers. Med"},{"key":"10.1016\/j.leukres.2024.107615_bib66","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-98255-7","article-title":"Target modulation and pharmacokinetics\/pharmacodynamics translation of the BTK inhibitor poseltinib for model-informed phase II dose selection","volume":"11","author":"Byun","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.leukres.2024.107615_bib67","first-page":"543","article-title":"Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia and lymphoma","volume":"14","author":"Varma","year":"2016","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"10.1016\/j.leukres.2024.107615_bib68","doi-asserted-by":"crossref","first-page":"969","DOI":"10.3899\/jrheum.200893","article-title":"Safety and efficacy of poseltinib, bruton's tyrosine kinase inhibitor, in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled, 2-part phase II study","volume":"48","author":"Genovese","year":"2021","journal-title":"J. Rheuma"},{"key":"10.1016\/j.leukres.2024.107615_bib69","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/bjh.14669","article-title":"Novel chemotherapy-free combination regimen for ibrutinib-resistant mantle cell lymphoma","volume":"181","author":"Srour","year":"2018","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2024.107615_bib70","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1182\/bloodadvances.2021006211","article-title":"Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitors","volume":"6","author":"Thompson","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2024.107615_bib71","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/leu.2014.263","article-title":"Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors","volume":"29","author":"Cheng","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2024.107615_bib72","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.clml.2015.02.021","article-title":"A phase II, single-arm, open-label, multicenter study to evaluate the efficacy and safety of P276-00, a cyclin-dependent kinase inhibitor, in patients with relapsed or refractory mantle cell lymphoma","volume":"15","author":"Cassaday","year":"2015","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.leukres.2024.107615_bib73","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/ijc.31044","article-title":"The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma","volume":"142","author":"Li","year":"2018","journal-title":"Int J. Cancer"},{"key":"10.1016\/j.leukres.2024.107615_bib74","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma","volume":"27","author":"Hess","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2024.107615_bib75","doi-asserted-by":"crossref","first-page":"4597","DOI":"10.1182\/blood-2011-10-388298","article-title":"Selective CDK4\/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma","volume":"119","author":"Leonard","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107615_bib76","doi-asserted-by":"crossref","DOI":"10.3390\/jpm12030376","article-title":"RelapsEd\/refractory mantle cell lymphoma: beyond BTK inhibitors","volume":"12","author":"Burkart","year":"2022","journal-title":"J. Pers. Med"},{"key":"10.1016\/j.leukres.2024.107615_bib77","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1158\/1078-0432.CCR-15-1527","article-title":"The addition of the BTK inhibitor Ibrutinib to Anti-CD19 chimeric antigen receptor T Cells (CART19) improves responses against mantle cell lymphoma","volume":"22","author":"Ruella","year":"2016","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.leukres.2024.107615_bib78","doi-asserted-by":"crossref","first-page":"8567","DOI":"10.1021\/acs.jmedchem.0c00967","article-title":"Global PROTAC toolbox for degrading BCR-ABL overcomes drug-resistant mutants and adverse effects","volume":"63","author":"Yang","year":"2020","journal-title":"J. Med Chem."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212624001814?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212624001814?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T10:37:26Z","timestamp":1778668646000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212624001814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":78,"alternative-id":["S0145212624001814"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2024.107615","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in the treatment of mantle cell lymphoma with BTK inhibitors","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2024.107615","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107615"}}